1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The NIDDK R21 page is a general overview of the R21 mechanism and does not contain specific sickle cell disease funding opportunity details or deadlines.
NIDDK Exploratory/Developmental Research Grant Program in Sickle Cell Disease (R21) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This opportunity supports mission-aligned projects and measurable outcomes related to sickle cell disease research. The R21 mechanism encourages the development of new research activities in categorical program areas.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the funder's website rather than a specific solicitation. Confirm program details with the funder.
R21: NIH Exploratory / Developmental Research Grant Award - NIDDK R21: NIH Exploratory / Developmental Research Grant Award The R21 grant mechanism encourages the development of new research activities in categorical program areas. NIDDK does not participate in the Parent R21 funding announcements . Applications must be submitted through an appropriate, targeted Notice of Funding Opportunity.
Current opportunities are in the areas of: Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed) Applicants should review “Eligibility Information” in the targeted funding opportunity. Applicants should review “Key Dates” in the targeted funding opportunity.
Potential applicants are strongly encouraged to contact “Agency Contacts” listed in the targeted funding opportunity before applying. Last Reviewed September 2025
According to the current listing, eligibility includes: Applicants should review “Eligibility Information” in the targeted funding opportunity. This is a national scope grant, so applicants across the U. S. may apply. Confirm the full requirements on the funder's own website before applying.
The current listing shows $275,000. Verify award ceilings, matching requirements, and allowable costs on the funder's own website.
Applications for NIDDK Exploratory/Developmental Research Grant Program in Sickle Cell Disease (R21) are due January 7, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIDDK Exploratory/Developmental Research Grant Program in Sickle Cell Disease (R21) is funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Verify program details on the funder's own website before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the funder's website linked on this page and look for its grants or funding section — the link goes to the funder's site rather than a specific solicitation.
NIH Organ-on-Chip Diabetes SBIR: Microphysiological Systems for Diabetes, Kidney, and Urologic Complications Research is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This highlighted topic encourages collaborative research applying human microphysiological systems (MPSs), or organ-on-chip platforms, to cell and tissue types relevant to diabetes and its kidney and urologic complications. High-priority areas include systems with at least two diabetes-relevant human tissues, validation of diabetes pathophysiology, studies of crosstalk between tissues, and models with mature cell types and interacting compartments.
NIDDK Small Business Programs (SBIR/STTR) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK participates in SBIR and STTR programs to support innovative research conducted by small businesses with the potential for commercialization. While their primary focus areas are digestive diseases, nutritional disorders, and obesity, innovations in medical devices that could have an impact on related circulatory or chronic conditions might be considered.